Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of an initial hormonal treatment
gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in
patients with histologically confirmed and advanced stages of prostate cancer. Their
characteristics, according to risk factors such as PSA and Gleason score will be determined
at baseline and 1, 3 and 6 month post-treatment.